This entry explains the term and why it shapes Arizona's requirements. It is not a treatment protocol and it is not a substitute for hands-on training in complication management. Every injector performing filler should have formal training in recognition and management, and every practice should have a written protocol reviewed by its medical director.
Vascular occlusion is the complication that separates filler from every other routine aesthetic service. It is the reason filler sits in a higher regulatory tier, the reason standing orders for filler must be more specific, and the reason a practice can be technically compliant on paper and still be dangerously unprepared.
What actually happens
Occlusion occurs in two ways. Filler can be injected directly into a vessel, or it can be placed alongside one in sufficient volume to compress it from outside. Either way the result is the same: blood stops reaching the tissue that vessel supplies.
Skin, like any tissue, dies without perfusion. If flow is not restored, the area progresses through blanching, mottling, and blistering to necrosis, which can leave permanent scarring. When filler enters vessels connected to the ophthalmic circulation, material can travel retrograde toward the retinal artery, and the resulting vision loss is frequently irreversible.
Recognition
| Sign | What it looks like | Timing |
|---|---|---|
| Disproportionate pain | Pain markedly exceeding what the procedure should cause. The most commonly rationalized sign. | Immediate to hours |
| Blanching | Sudden pallor or white patches in the treated distribution. | Immediate |
| Livedo reticularis | Dusky, mottled, net-like discoloration. | Minutes to hours |
| Delayed capillary refill | Slow return of colour after pressure. | Immediate to hours |
| Visual change | Blurring, field loss, or severe pain around the eye. Time-critical. | Immediate |
| Cool skin | The affected area feels cooler than surrounding tissue. | Hours |
The characteristic mistake is not failing to recognize occlusion — it is recognizing it and hesitating. An injector sees blanching, hopes it is pressure-related, and decides to review the patient tomorrow. The standard of care is to treat on suspicion. Dissolving filler unnecessarily costs a result. Waiting can cost tissue.
Why this drives Arizona's requirements
Everything Arizona expects of a filler practice follows from the clinical facts above. Because the window is short, the plan must pre-exist the event. Because HA filler is reversible, the reversal agent must be physically present. Because the injector may be an RN working without a prescriber in the building, the escalation path has to be written down and usable by that nurse alone.
That is the entire logic behind Level III classification: a written vascular-emergency protocol, hyaluronidase on site, trained staff, and a documented escalation route. Your standing order for filler is where those requirements live.
What a usable protocol contains
- Recognition criteria stated plainly enough to act on without second-guessing.
- Immediate steps — stop injecting, and proceed per your protocol.
- Hyaluronidase guidance — location, dosing reference, and repeat parameters, for HA filler.
- Who to call, in order, with numbers that work after hours.
- An ophthalmology route for any periocular or visual involvement.
- Documentation requirements — what to record, and when.
- Patient follow-up — intervals and what to monitor.
The test of a protocol is not whether it exists. It is whether the least experienced injector on your schedule could follow it correctly at 7pm on a Saturday with nobody senior in the building.
Frequently asked
How quickly does vascular occlusion need to be treated?
Immediately. This is not a complication to observe overnight or to address at the next available appointment. The accepted approach is to treat on suspicion rather than waiting for certainty, because the tissue consequences of delay are far worse than the consequences of dissolving filler that turns out not to have been occlusive.
What are the warning signs?
Pain disproportionate to the procedure, immediate blanching or unusual pallor, a dusky or mottled discoloration described as livedo reticularis, delayed capillary refill, and in periocular cases visual changes or severe headache. Pain out of proportion is the one injectors most often talk themselves out of.
Can vascular occlusion be reversed?
Hyaluronic acid fillers can be dissolved with hyaluronidase, which is why HA products are the safer choice for anyone still building experience. Non-HA fillers such as calcium hydroxylapatite and poly-L-lactic acid cannot be dissolved, so an occlusion involving them is managed supportively and is considerably more dangerous.
Which areas carry the highest risk?
The glabella, the nose, and the nasolabial region are classically the highest-risk zones because of their vascular anatomy and connections to the ophthalmic circulation. The periocular area carries the specific risk of vision loss. This is precisely why zone-specific authorization in a standing order matters more for filler than for neuromodulators.
Does every practice performing filler need hyaluronidase on site?
If you inject HA filler, yes — present in the building, in date, and known to the staff who would need it. Hyaluronidase that is on order, at another location, or expired is functionally absent during the window when it would matter.